Platelet Changes in Type 2 Diabetes

Platelet Indices Changes in Type 2 Diabetes Mellitus and Their Relationship With Inflammatory Markers

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07363122

Enrollment

200

Registered

2026-01-23

Start date

2026-02-01

Completion date

2027-03-01

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Markers, Platelet Indices, Type 2 Diabetes

Keywords

Platelets, Platelet indices, T2DM, Type 2 Diabetes Mellitus, inflammatory markers

Brief summary

This study examines changes in platelet indices in people with type 2 diabetes compared to healthy people. It checks if these changes relate to inflammation markers (like hs-CRP) and blood sugar control. Participants get routine blood tests during one clinic visit at Assiut University Hospitals. No treatments or extra procedures are involved.

Detailed description

Type 2 Diabetes Mellitus (T2DM) is characterized by chronic low-grade inflammation and hyperglycemia, which may alter platelet activation and morphology, potentially increasing cardiovascular risk. This cross-sectional case-control study aims to evaluate platelet indices, specifically mean platelet volume (MPV), platelet distribution width (PDW), platelet-large cell ratio (P-LCR), and plateletcrit (PCT), in T2DM patients compared to healthy controls. Additionally, it investigates the correlation between these indices and inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR), as well as glycemic parameters such as fasting blood glucose, postprandial blood glucose, and glycosylated hemoglobin (HbA1c). The study will be conducted at Assiut University Hospitals and clinics, enrolling 100 adult patients (aged 30-70 years) diagnosed with T2DM for at least one year and 100 healthy age-matched controls. Exclusion criteria include type 1 diabetes, acute infections, malignancies, chronic inflammatory or hematologic diseases, recent major surgery or trauma, and current use of anti-platelet or anti-inflammatory medications. All participants will undergo a complete medical history, clinical examination, and blood sampling for complete blood count (CBC) and biochemical analysis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Adults aged 30-70 years. * Diagnosed T2DM for at least 1 year. * Fasting blood glucose ≥126 mg/dL and/or HbA1c ≥ 6.5%

Exclusion criteria

* Type 1 Diabetes Mellitus * Acute infection, chronic inflammatory disease * Malignancy. * Current use of anti-platelet or anti-inflammatory medications * Chronic liver, renal, or hematologic disease * Recent major surgery or trauma (within 3 months)

Design outcomes

Primary

Measure	Time frame	Description
Mean Platelet Volume (MPV)	Single measurement at enrollment	Difference in mean platelet volume (MPV) measured from complete blood count between T2DM patients and healthy controls. MPV reflects platelet activation and size, expected to be elevated in T2DM due to inflammation and hyperglycemia.

Secondary

Measure	Time frame	Description
High-sensitivity C-reactive Protein (hs-CRP)	Single measurement at enrollment	Serum levels of high-sensitivity C-reactive protein (hs-CRP) in T2DM patients compared to healthy controls, as a marker of systemic inflammation potentially linked to platelet changes.

Outcome results